Montelukast is classified as L4 in Hale's Medications & Mothers' Milk 2021 and 2023 due to FDA's warning. I am not quite sure about the current recommendation, how we can manage 'breastfeeding and pumping' if the mother takes this medication because her physician prescribes it and said the use of Montelukast is not significantly related to suicidal actions, etc. Thank you so much for your suggestions.
Announcement
Collapse
No announcement yet.
Welcome to our forum! Before posting your questions, please read the following terms:
- 1. Forum questions will be responded to by InfantRisk staff as schedules permit during normal business hours.
- 2. This forum is not intended for emergencies or urgent care. For any immediate medical concerns, please seek appropriate medical attention.
- 3. Any statements made by team members should be discussed with your medical care team. Your healthcare providers know you (and your baby) best, and should have a better understanding of your unique situation.
- 4. We are a small team dedicated to helping you as best as we can. However, for the quickest response, we recommend calling the InfantRisk Center at +1(806) 352-2519.
By posting to the forums, you acknowledge and agree to these terms.
The InfantRisk team
Montelukast (Singulair) in Hale's Medications & Mothers' Milk (2023)
Collapse
X
-
We changed the Montelukast back to a L3. It was an L4 because the FDA added a Black Box warning over the pediatric use of montelukast, which included side effects such as serious behavior and mood-related change, and suicide in users. She should be able to take this medication and do full breastfeeding. The benefits should outweigh the risks. It is very low transfer into the breastmilk. Untreated asthma is dangerous. Monitor baby for irritability, drowsiness, and diarrhea.
Alicia Nelson RN
Infant Risk Center
Comment